Pfizer's tofacitinib positive in Phase II for ulcerative colitis
This article was originally published in Scrip
Executive Summary
Patients with moderately to severely active ulcerative colitis were more likely to have clinical response and remission when treated with Pfizer's oral JAK-inhibitor tofacitinib than those receiving placebo, a Phase II study in the New England Journal of Medicine shows. Pfizer has recently initiated Phase III studies in this indication.